The Food and Drug Administration (FDA) has approved several CDx methods for PD-1 immunotherapy, such as the use of PD-L1 22C3 monoclonal antibody for immunohistochemical staining of tumour tissue from patients with non-small-cell lung carcinoma (NSCLC). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.